Tag Archives: Medicines Australia

Medicines Australia Transparency Working Group Releases Reports

The documents, “Principles for transparency” and “Transparency model consultation and discussion document” are now available. For comment see: Harvey K. Slow path to transparency. MJA Insight, July 1, 2013. https://www.mja.com.au/insight/2013/24/ken-harvey-slow-path-transparency Coleman J. GPs will gain from greater transparency. 6 Minutes Q&A, July … Continue reading

Posted in Pharmaceutical Promotion | Tagged , , | Leave a comment

Transcripts now available: Therapeutic Goods Amendment (Pharmaceutical Transparency) Bill 2013

See: Finance and Public Administration Legislation Committee; Monday, 29 April 2013 by

Posted in Pharmaceutical Promotion, Senate | Tagged , | Leave a comment

Melbourne Senate Public Hearing: Therapeutic Goods Amendment (Pharmaceutical Transparency) Bill 2013

On Monday, April 29, 2013 I’m appearing before a  Senate committee to give evidence about this bill put up by Greens Senator Richard Di Natale. The committee is looking at the need for regulation of pharmaceutical industry conduct with regards to interactions with the … Continue reading

Posted in Pharmaceutical Promotion, Senate | Tagged , | Leave a comment

Submission re Senate Therapeutic Goods Amendment (Pharmaceutical Transparency) Bill 2013

Now posted on the Senate web site along with others. Today is the last day for submissions so I guess more will show up next week. by

Posted in Pharmaceutical Promotion, Senate | Tagged , | Leave a comment

Gave talk to ARCS Melbourne Regional Networking Group,

Self-regulation versus co-regulation: A consumer perspective. Noted that submissions to Greens Senator Di Natale Therapeutic Goods Amendment (Pharmaceutical Transparency) Bill 2013 should be lodged by 19 April 2013 to the Finance and Public Administration Legislation Committee. Reiterated that legislation is required to make compliance … Continue reading

Posted in Pharmaceutical Promotion, Senate | Tagged , , | Leave a comment

Published comment on MJA Insight: Vital transparency

http://www.mjainsight.com.au/view?post=ken-harvey-vital-transparency&post_id=11651&cat=comment FULL disclosure of the relationship between therapeutic goods companies, doctors and other stakeholders is currently in the hands of the Australian Competition and Consumer Commission. The ACCC is currently deciding if it will give the go-ahead to the 17th … Continue reading

Posted in Pharmaceutical Promotion | Tagged , , , , , , | Leave a comment

Australian Skeptic National Convention December 1-2, 2012

I was delighted to be able to contribute to this excellent program: In a panel discussion with colleagues, “Active Skepticism: An Evidence-Based Approach to Medical Treatment” and A talk titled, “Confessions of a Serial Complainant: Why Take On the Therapeutic … Continue reading

Posted in Pharmaceutical Promotion | Tagged , , , , , , , | Leave a comment

ACCC Pre-decision conference: Medicines Australia Code

At yesterday’s meeting with the ACCC, Ian Haines, Bob Arnold, Carol Bennett, Ray Moynihan and I argued that full disclosure of the relationship between therapeutic goods companies, physicians and other stakeholders is crucial. I tabled a petition that currently has … Continue reading

Posted in Pharmaceutical Promotion | Tagged , , | Leave a comment

Petition to ACCC on Medicines Australia Code Authorisation

While collaborations between industry and health professionals are desirable, widespread financial ties bring significant risks of undue influence on professional judgements, potentially jeopardizing the integrity of medical research, education, clinical practice and public trust in medicine, according to a landmark … Continue reading

Posted in Pharmaceutical Promotion | Tagged , , , , | Leave a comment

ACCC now posting submissions on Medicines Australia Code

See: http://www.accc.gov.au/content/index.phtml/itemId/1063694/fromItemId/278039/display/submission The AMA’s submission to the ACCC is also available at:  http://ama.com.au/print/8101 “The AMA therefore commends Medicines Australia’s proposal to work further with stakeholders on the issue of public reporting on pharmaceutical companies interactions with individual healthcare professionals”. Reminiscent … Continue reading

Posted in Pharmaceutical Promotion | Tagged , , | Leave a comment